L-cinerulose A | 25881-96-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 氧烷类
• 英文名称: L-cinerulose A
• 英文别名: L-cinerulose；(2S)-6-hydroxy-2-methyloxan-3-one
• CAS: 25881-96-3；33985-39-6
• 化学式: C₆H₁₀O₃
• 分子量: 130.144
• InChiKey: COVKNBOLMSOOOY-VKZKZBKNSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.1
• 重原子数：
  9
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.83
• 拓扑面积：
  46.5
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  [(1S)-1-(furan-2-yl)ethyl] 2-phenylacetate 在 sodium hydroxide 、 palladium on activated charcoal 、 氢气 、 间氯过氧苯甲酸 作用下， 生成 L-cinerulose A
  参考文献：
  名称：

  A new access to chiral 2-furylcarbinols by enantioselective hydrolysis with penicillin acylase

  摘要：

  DOI：

  10.1016/s0040-4039(00)99401-2

文献信息

• Olefin cross metathesis based de novo synthesis of a partially protected L-amicetose and a fully protected L-cinerulose derivative
  作者：Bernd Schmidt、Sylvia Hauke

  DOI：10.3762/bjoc.10.102

  日期：——

  Cross metathesis of a lactate derived allylic alcohol and acrolein is the entry point to a de novo synthesis of 4-benzoate protected L-amicetose and a cinerulose derivative protected at C5 and C1.

  乳酸酯衍生的烯丙醇和丙烯醛的交叉复分解是从头合成 4-苯甲酸酯保护的 L-乙酰氨基葡萄糖和 C5 和 C1 保护的蜡菊糖衍生物的切入点。
• New Anthracycline Antibiotic CG12 Obtained by Microbial Glycosidation of<i>α</i>-Citromycinone
  作者：Osamu Johdo、Akihiro Yoshimoto、Tomoyuki Ishikura、Hiroshi Naganawa、Tomio Takeuchi、Hamao Umezawa

  DOI：10.1080/00021369.1986.10867629

  日期：1986.6
• WALDMANN, HERBERT, TETRAHEDRON LETT., 30,(1989) N3, C. 3057-3058
  作者：WALDMANN, HERBERT

  DOI：——

  日期：——
• [EN] ANTIBIOTIC FIIRV 104/18 COMPLEX AND THE ISOLATED INDIVIDUAL FACTORS THEREOF<br/>[FR] COMPLEXE ANTIBIOTIQUE FIIRV 104/18 ET FACTEURS INDIVIDUELS ISOLÉS DE CE DERNIER
  申请人：FOND ST INSUBRICO DI RICERCA PER LA VITA

  公开号：WO2017093114A1

  公开（公告）日：2017-06-08

  An antibiotic FIIRV 104/18 complex comprising factors F793, F795, F797, F813 and F683, of formula (I), wherein R represents a glycosidic radical as defined in the specification, the isolated individual factors, a method for their production by cultivation of Dactylosporangium FIIRV sp. 104/18 DSM 32068 under aerobic conditions, and pharmaceutical formulations containinig them as active ingredient and their use in the treatment of bacterial infections, caused by bacteria of at least one of the genera Enterococci, Streptococci, Staphylococci and Moraxella, including bacteria of multi resistant strains, in particular Staphylococcus spp., Streptococcus spp, and Enterococcus spp. resistant to methicillin and/or vancomycin.